These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 31496046

  • 1. Lymphocyte subset at time of Epstein-Barr viremia post-allogeneic hematopoietic stem cell transplantation in children may predict development of post-transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor.
    Althubaiti S, Ali S, Renzi S, Krueger J, Chiang KY, Schechter T, Punnett A, Ali M.
    Pediatr Transplant; 2019 Dec; 23(8):e13574. PubMed ID: 31496046
    [Abstract] [Full Text] [Related]

  • 2. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
    Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF.
    Blood; 2000 Dec 15; 96(13):4055-63. PubMed ID: 11110673
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L.
    Pediatr Nephrol; 2017 Aug 15; 32(8):1433-1442. PubMed ID: 28280938
    [Abstract] [Full Text] [Related]

  • 6. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Nishio H, Matsuo M, Imadome K, Iijima K.
    Eur J Pediatr; 2014 Dec 15; 173(12):1615-8. PubMed ID: 24169729
    [Abstract] [Full Text] [Related]

  • 7. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ.
    J Clin Virol; 2012 Mar 15; 53(3):186-94. PubMed ID: 22182950
    [Abstract] [Full Text] [Related]

  • 8. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY, Mo XD, Xu LP, Zhang XH, Wang Y, Liu KY, Chang YJ, Zhao XY, Huang XJ.
    Ann Hematol; 2020 Nov 15; 99(11):2649-2657. PubMed ID: 32206854
    [Abstract] [Full Text] [Related]

  • 9. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.
    Mensen A, Na IK, Häfer R, Meerbach A, Schlecht M, Pietschmann ML, Gruhn B.
    J Cancer Res Clin Oncol; 2014 Nov 15; 140(11):1971-80. PubMed ID: 24962343
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, Sun A, Wu D.
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb 15; 37(2):138-43. PubMed ID: 27014984
    [Abstract] [Full Text] [Related]

  • 12. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 15; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 13. Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.
    Burns DM, Ryan GB, Harvey CM, Nagy E, Hughes S, Murray PG, Russell NH, Fox CP, Long HM.
    Front Immunol; 2019 Sep 15; 10():2489. PubMed ID: 31736946
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD, Durand KA, Solernou V, Bosaleh A, Balbarrey Z, García de Dávila MT, Rodríguez M, Irazu L, Alonio LV, Picconi MA.
    Rev Argent Microbiol; 2016 Sep 15; 48(2):110-8. PubMed ID: 27157146
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A, Liu Y, Walker JT, Fonseca K, Daly A, Duggan P, Stewart D, Russell JA, Storek J.
    Bone Marrow Transplant; 2011 Aug 15; 46(8):1104-12. PubMed ID: 21057556
    [Abstract] [Full Text] [Related]

  • 18. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Aug 15; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 19. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun 15; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 20. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Cytotherapy; 2018 May 15; 20(5):706-714. PubMed ID: 29580864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.